Literature DB >> 26772924

Should a Preschool Child with Acute Episodic Wheeze be Treated with Oral Corticosteroids? A Pro/Con Debate.

Avraham Beigelman1, Sandy Durrani2, Theresa W Guilbert3.   

Abstract

Traditionally, preschool-aged children with an acute wheezing episode have been treated with oral corticosteroids (OCSs) based on the efficacy of OCSs in older children and adolescents. However, this practice has been recently challenged based on the results of recent studies. The argument supporting the use of OCSs underscores the observation that many children with recurrent preschool wheezing develop atopic disease in early life which predicts both an increased risk to develop asthma in later life and response to OCS therapy. Further, review of the literature demonstrates heterogeneity of study designs, OCS dosage, interventions, study medication adherence, and settings and overall lack of predefined preschool wheezing phenotypes. The heterogeneity of these studies does not allow a definitive recommendation discouraging OCS use. Advocates against the use of OCSs in this population argue that most of studies investigating the efficacy of OCSs in acute episodic wheeze in preschool-aged children have not demonstrated beneficial effects. Moreover, repeated OCS bursts may be associated with adverse effects. Finally, both sides can agree that there is a significant need to conduct efficacy trials evaluating OCS treatment in preschool-aged children with recurrent wheezing targeted at phenotypes that would be expected to respond to OCSs. This article presents a summary of recent literature regarding the use of OCSs for acute episodic wheezing in preschool-aged children and a "pro" and "con" debate for such use.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26772924     DOI: 10.1016/j.jaip.2015.10.017

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  4 in total

1.  The routine use of oral steroids in paediatric asthma is not routine.

Authors:  Brian A Kuzik
Journal:  Paediatr Child Health       Date:  2018-04-07       Impact factor: 2.253

Review 2.  Management of preschool recurrent wheezing and asthma: a phenotype-based approach.

Authors:  Avraham Beigelman; Leonard B Bacharier
Journal:  Curr Opin Allergy Clin Immunol       Date:  2017-04

3.  Challenges in assessing the efficacy of systemic corticosteroids for severe wheezing episodes in preschool children.

Authors:  Theresa W Guilbert; Leonard B Bacharier; David T Mauger; Wanda Phipatanakul; Stanley J Szefler; Susan Boehmer; Avraham Beigelman; Anne M Fitzpatrick; Daniel J Jackson; Sachin N Baxi; Mindy Benson; Carey-Ann D Burnham; Michael D Cabana; Mario Castro; James F Chmiel; Ronina Covar; Michael Daines; Jonathan M Gaffin; Deborah A Gentile; Fernando Holguin; Elliot Israel; H William Kelly; Stephen C Lazarus; Robert F Lemanske; Ngoc Ly; Kelley Meade; Wayne Morgan; James Moy; J Tod Olin; Stephen P Peters; Jacqueline A Pongracic; Hengameh H Raissy; Kristie Ross; William J Sheehan; Christine Sorkness; W Gerald Teague; Shannon Thyne; Fernando D Martinez
Journal:  J Allergy Clin Immunol       Date:  2019-01-17       Impact factor: 10.793

4.  Management of Preschool Wheezing: Guideline from the Emilia-Romagna Asthma (ERA) Study Group.

Authors:  Valentina Fainardi; Carlo Caffarelli; Michela Deolmi; Kaltra Skenderaj; Aniello Meoli; Riccardo Morini; Barbara Maria Bergamini; Luca Bertelli; Loretta Biserna; Paolo Bottau; Elena Corinaldesi; Nicoletta De Paulis; Arianna Dondi; Battista Guidi; Francesca Lombardi; Maria Sole Magistrali; Elisabetta Marastoni; Silvia Pastorelli; Alessandra Piccorossi; Maurizio Poloni; Sylvie Tagliati; Francesca Vaienti; Giuseppe Gregori; Roberto Sacchetti; Sandra Mari; Manuela Musetti; Francesco Antodaro; Andrea Bergomi; Lamberto Reggiani; Fabio Caramelli; Alessandro De Fanti; Federico Marchetti; Giampaolo Ricci; Susanna Esposito
Journal:  J Clin Med       Date:  2022-08-15       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.